EcoDrugPlus

Atpase Na+/k+ Transporting Subunit Beta 3

Ensembl ID : ENSGEVG00005010202
Gene Symbol: ATP1B3
3 Cross references
296 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atr Serine/threonine Kinase

Ensembl ID : ENSGEVG00005008879
Gene Symbol: ATR
3 Cross references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Axl Receptor Tyrosine Kinase

Ensembl ID : ENSGEVG00005016231
Gene Symbol: AXL
1 Cross references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSGEVG00005008906
Gene Symbol: BRAF
3 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Apoptosis Regulator

Ensembl ID : ENSGEVG00005003964
Gene Symbol: BCL2
3 Cross references
228 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Like 1

Ensembl ID : ENSGEVG00005008274
Gene Symbol: BCL2L1
1 Cross references
289 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Like 10

Ensembl ID : ENSGEVG00005004076
Gene Symbol: BCL2L10
2 Cross references
129 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Related Protein A1

Ensembl ID : ENSGEVG00005007639
Gene Symbol: BCL2A1
1 Cross references
133 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSGEVG00005004923
Gene Symbol: BCR
1 Cross references
287 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bruton Tyrosine Kinase

Ensembl ID : ENSGEVG00005012557
Gene Symbol: BTK
3 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Chemokine Receptor Type 5-Like

Ensembl ID : ENSGEVG00005003928
Gene Symbol: LOC115645896
2 Cross references
486 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-C Chemokine Receptor Type 5-Like

Ensembl ID : ENSGEVG00005003949
Gene Symbol: LOC115645900
2 Cross references
487 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).